Member Info for Saxondale

Frankly Donald that's not exactly what is happening here .
You find biomarkers in order to help you predict the response to certain treatments .
The worlds leading Immunotherapy drug Keytruda uses such biomarkers as MSI-H , dMMR and PD-L1 in order to predict whether their drug will be right for you .
This field is all about identifying markers to help you select patients for the right treatments , and the right cancers .
Its no wonder that the numbers get reduced once you start fine tuning .
Yes , Bex will not perhaps help the majority of patients , but nor does Keytruda .
Once you have identified the markers , and select patients based on that criteria , you start to get a very targeted and effective drug .
If this had hit £4 today on the back of this news , would you have just sold and moved on ?
I'm not sure what the panic is . We've all been invested here for quite a while , and we know how pharma co's work don't we ?
Todays announcement should be celebrated as a big step forward helping get Bex in the right shape for the pivotal trials - because selecting this subgroup in future trials could easily double the efficacy results .

As for ending up with only 3 cancer types that fit this model , I don't call that a disaster . Just finding a therapy to treat one would be enough to command a big price tag .

And the discovery that Interferon gamma is key to igniting the immune response , and Bex being responsible for that , makes the case for its further potential as a neoadjuvant even more promising .

How anybody can be negative about todays RNS is beyond me .

You might as well just sell up and move onto a better prospect in that case .

Great little interview for long term holders .
For a company lining up multiple trial arms for their therapy , to get a discovery like this is the cherry on the cake .

Reading through the RNS text - there is a lot in there - and worth a re-read . It really does highlight how much of a groundbreaking step this is , and what potential Bex has .

OK the SP only crawled up a bit , but I think it's primed for a rerate shortly . Big Pharma will be watching this very closely .
And what $ value has this discovery just added to the package ? Quite a bit I would say .

The screening method being a simple blood test also makes life alot easier - no expensive and intrusive biopsy as with other treatments .

Still waiting on the dosing decision - ie soluble clever1 . That will be the major piece of the jigsaw needed to proceed to P3 .
Good news is that if optimum dosing is weekly and with high dose , then it's still massively inside the safety zone , and still perfectly safe to run as a combi or monotherapy .

So H1 2022 is when he expects this to get sorted - then talk to FDA

Wise he did not mention any SSW , he kept things very scientific - but we know that the Bex package is getting more attractive with every update like this .

Yep , they would buy my shares for 14.05 quite happily on the bell .

Keep going with the positivity silver - you've nearly nudged this back to 14p already !
Just be prepared for a bumpy ride . this never went up in a straight line the first time .

Just have to take advantage of this drop . I thought I'd finished , but couldn't resist one more bite .
I mean i wanted more anyway - and this morning they are on sale again .
Pretty chuffed with 13.08p
Famous last words , but either way they're mine now lol

Nas is over 7% up at the moment .

- sorry , responsive to PD-1 inhibitor treatment I meant to say .
That's handy as they have plans to run such a trial shortly ( according to the latest pipeline presentation - in conjunction with UT Health San Antonio .

Well this is some positive news !
Selecting patients through a simple blood test for Interferon gamma , for those most likely to benefit .
That will increase success rate percentages incredibly .
This is what the aim of finding the biomarkers is all about .
And to prove it up is great news - meaning Bex really is starting to stand out as a well understood treatment .

And I love the comment as how it is acting as a catalyst to promote patients to become responsive .

Well done Faron .

Just in case anyone wants to check on upcoming events
https://www.faron.com/investors/calendar

Ok , we were all expecting updates in Q4 . Not much time left , so what comes , comes .

At least they seem to be busy booking slots for Jan 2022 , so perhaps at least that is a signal that they will be wanting to present some new slides .

Two more bookings made today ,
10-13Jan - HC Wainwright Bioconnect conference
25th Jan - Swiss Nordic Bio Invitation - Annual Heathcare Conference .

Me too . A couple of £2ks was all I could manage to spare .
Thats it now - dumped two other shares that I really didn't care about .
Portfolio lean as a whippet now .
Less to worry about .
This is my only gold share now , in fact only mining share .
Funds parked up here now until we hit ATH again , however long it takes .
Roll on the updates , and lets see how we go during 2022 .

It would be interesting if anyone has data on the % of hospitalised patients with Covid suffering from breathlessness and needing treatment - who were also asthma or COPD sufferers .
When Covid broke out , most people would have assumed that those folk , along with other respiratory sufferers , would have the toughest time and be most vulnerable . I don't know if that is true ?
This data at least shows that having asthma or COPD doesn't affect the way SNG001 works it seems .
There must be a point when the lung tissues are so damaged ( fluid filled ) that nebulised delivery is ineffective , so its reassuring again to see data that proves that these patients also respond well to SNG001.

Certainly some positive vibes in that presentation summary.
I like this bit - We presented data showing that SNG001 activates the lungs’ antiviral defences for 24
hours after a dose has been delivered, supporting our once-a-day dosing schedule .
So for the whole treatment period , the drug is effective .
Well tolerated . Again a big tick .
Biomarker responses were similar in younger asthma patients and older COPD patients
at the same dose. So effective in young and old , again a big tick .

Like many on here have noted - we are going to subject to a lot of fun , games and shenanigans with the SP while we wait for P3 . The good thing is , early 2022 isn't too far away - what with Christmas and New Year - we are only a matter of weeks away now from Sprinter news , and that's if we don't get other news first .

Costa Rica site added to the study locations on Activ2 trial today .
First one for that country .

I guess If you were a delegate , and paid your £500 , you'd want a little exclusivity for a while at least , and perhaps that entitles them to a little more detail and questions answered within that closed space .
If there was anything materially new however , that has been presented to people outside of the company , I would expect an RNS at some point in the next day or so , even if it was just some bullet points .
If we don't get one , then at least its been a good showcase in front of the right people , and a reminder of what SNG001 can do .
I still think we may well get one though .

What a great RNS . And I'm glad that there was no end comment stuck in there about SP , as this news is big enough that it didn't need any fluff around it .

Lets face it , if I had seen the presentation ( which I haven't) , and it had some juicy good stuff in it , the last thing I'd be doing is posting it up here tonight , just in case it doesn't get RNS'd first thing , so I'd get first dabs at some cheap shares in the morning . I reckon if its worthy of an Oral presentation , we should get an RNS with the abstract highlights tomorrow .
Otherwise it's a bit mean to RNS the event , then not show us , since 99% of us wouldn't be registered to view it.

I stuck something about the EIC being the 7th biggest shareholder now on Twitter , and coincidentally , it turns out Faron were at an EIC get together last week .
Looks like the relationship is building well .

Also Faron have just added a date to the calendar - 27th Jan 2022 - Proactive Forum One2One Investor Event .

The oral presentation will highlight clinical data demonstrating the antiviral activity of SNG001 in the lungs of patients with asthma and those with chronic obstructive pulmonary disease (COPD).

This is the main offering then - so do they have new data on the Asthma and COPD patients ?

Abstracts will normally get posted on the day they are presented ( if they are late breaking ) . So as this is after trading hours today , expect a late RNS after hours or tomorrow with the content perhaps .
This could just be old data , but the note about article 7 suggests there is new information . Otherwise it would just be a RNS Reach style notification .